"As complex as the business of biotechnology has proven to be, there are few venues for thoughtful exchanges of ideas and opinions. The Journal of BioLaw & Business should appeal to all participants in the field."

T. Forcht Dagi, MD, MPH, MBA, Managing Partner, Cordova
Ventures/Board of Advisors, Wharton School for Entrepreneurship

“BioLaw is must reading for anyone concerned about biotech and life science issues. It covers research to royalties and everything in between. The articles and regular columns feature a unique blend of academic and practical insights from all of the relevant disciplines. I strongly recommend it."

Professor Mark Rothstein, JD, Director, Institute for Bioethics,Health Policy and Law /p>

“A thoughtful publication bringing together unique insights into strategy, business and law in biotech and pharma."

Stelios Papadopoulos,PhD, Managing Director, Investment Banking, SG Cowen Securities /p>

“Substantive…concise…practical…and at the center of the next new wave…BioLaw is a ‘must-read’ for those who want to be there.“

Gordon R. Penman, Esq. Partner/Management Committee, Brown Rudnick Berlack Israels, LLP;
Managing Director, Venture Capital Fund of New England

“BioLaw has a remarkably useful and authoritative array of articles in columns in the regulatory, business, legislative, legal and public policy arenas – so important to successful application of advances in biotechnology – both in the public and private sectors.”

Gilbert Omenn, MD, PhD,
Executive Vice President for Medical Affairs,
University of Michigan